Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER COLE LAGANKE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1811931546
CMS profile
127886
Location
CULLMAN, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$161,474.55

315 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER COLE LAGANKE

NPI 1811931546 · CMS profile ID 127886

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CULLMAN, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811931546?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER COLE LAGANKE, NPI 1811931546, CMS profile ID 127886. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811931546?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHRISTOPHER COLE LAGANKE, NPI 1811931546, CMS profile ID 127886. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811931546?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHRISTOPHER COLE LAGANKE, NPI 1811931546, CMS profile ID 127886, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1811931546?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

315 matching records · $161,474.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 315 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 315.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $16.8911/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576735 CMS
UCB, Inc. $16.9011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688342689 CMS
Biogen, Inc. $15.6410/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608973 CMS
EISAI INC. $12.7010/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697018495 CMS
Acorda Therapeutics, Inc $11.8710/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498447 CMS
Biogen, Inc. $12.8510/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608967 CMS
GENZYME CORPORATION $2,818.0010/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694231431 CMS
GENZYME CORPORATION $3,185.0010/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694231433 CMS
GENZYME CORPORATION $62.6410/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694231435 CMS
Mallinckrodt Enterprises LLC $12.1710/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704808661 CMS
Genentech USA, Inc. $14.2410/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681361697 CMS
Biogen, Inc. $4,725.0010/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608913 CMS
Biogen, Inc. $128.7610/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608915 CMS
Biogen, Inc. $33.0010/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608921 CMS
Biogen, Inc. $14.0810/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608969 CMS
Mallinckrodt Enterprises LLC $6,800.0010/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704808659 CMS
Novartis Pharmaceuticals Corporation $2,660.0010/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576719 CMS
Novartis Pharmaceuticals Corporation $16.7710/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576721 CMS
Novartis Pharmaceuticals Corporation $2,660.0010/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576723 CMS
Novartis Pharmaceuticals Corporation $13.4510/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576725 CMS
Novartis Pharmaceuticals Corporation $98.6010/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576733 CMS
Biogen, Inc. $1.1010/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608971 CMS
Mallinckrodt Enterprises LLC $456.0010/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704808657 CMS
Mallinckrodt Enterprises LLC $17.6210/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704808655 CMS
UCB, Inc. $1.3010/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688321289 CMS
UCB, Inc. $17.9310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688347271 CMS
GENZYME CORPORATION $1,225.0010/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694220075 CMS
Novartis Pharmaceuticals Corporation $13.4210/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576729 CMS
Novartis Pharmaceuticals Corporation $11.0110/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576767 CMS
Novartis Pharmaceuticals Corporation $2,660.0010/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576711 CMS
Novartis Pharmaceuticals Corporation $16.5010/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576713 CMS
Novartis Pharmaceuticals Corporation $2,660.0010/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576715 CMS
Novartis Pharmaceuticals Corporation $17.3710/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576717 CMS
Novartis Pharmaceuticals Corporation $86.4210/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576731 CMS
Biogen, Inc. $4,200.0010/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608989 CMS
Biogen, Inc. $82.3610/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608991 CMS
Biogen, Inc. $45.9910/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608993 CMS
Greenwich Biosciences, Inc. $24.8210/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701803461 CMS
Novartis Pharmaceuticals Corporation $11.5609/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659576699 CMS
Biogen, Inc. $15.0909/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608965 CMS
Genentech USA, Inc. $1.9709/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681389013 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.4509/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681901873 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.8009/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682075801 CMS
Genentech USA, Inc. $13.1509/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681398469 CMS
UCB, Inc. $16.9009/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688283031 CMS
Amgen Inc. $19.9809/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662253249 CMS
Biogen, Inc. $4.3809/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660608963 CMS
EMD Serono, Inc. $16.2209/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702984751 CMS
GENZYME CORPORATION $3,920.0009/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694177801 CMS
GENZYME CORPORATION $63.8009/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694314145 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $161,474.55 315
PY2020 $66,122.93 283
PY2021 $64,793.83 314
PY2022 $83,819.46 341
PY2023 $104,589.49 329
PY2024 $124,245.98 330
PY2025 $105,565.30 350

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $765,979.02 107
PY2024 Principal investigator $788,549.79 95
PY2023 Principal investigator $914,627.35 57
PY2022 Recipient $1,250.00 1
PY2022 Principal investigator $631,531.72 43
PY2021 Recipient $1,500.00 4
PY2021 Principal investigator $737,810.06 50
PY2020 Recipient $4,553.41 17
PY2020 Principal investigator $618,598.02 49
PY2019 Recipient $4,895.40 16
PY2019 Principal investigator $700,785.24 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $23.31 12/29/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199999
Principal investigator 1 Genentech, Inc. $2,370.00 12/19/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629999
Principal investigator 1 TG Therapeutics, Inc. $23.31 12/18/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199997
Principal investigator 1 TG Therapeutics, Inc. $4,604.85 12/09/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199985
Principal investigator 1 TG Therapeutics, Inc. $4,002.90 12/08/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199977
Principal investigator 1 Genentech, Inc. $7,355.00 12/04/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629950
Principal investigator 1 Genentech, Inc. $2,644.00 11/20/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629994
Principal investigator 1 TG Therapeutics, Inc. $23.31 11/18/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199995
Principal investigator 1 GENZYME CORPORATION $38,216.85 11/17/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095343
Principal investigator 1 GENZYME CORPORATION $15,974.59 11/17/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095349
Principal investigator 1 TG Therapeutics, Inc. $93.24 11/13/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199993
Principal investigator 1 TG Therapeutics, Inc. $4,000.00 11/13/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200013
Principal investigator 1 TG Therapeutics, Inc. $4,724.40 11/01/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199983
Principal investigator 1 TG Therapeutics, Inc. $24.70 10/29/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199991
Principal investigator 1 TG Therapeutics, Inc. $23.31 10/23/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199989
Principal investigator 1 GENZYME CORPORATION $119.06 10/20/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095332
Principal investigator 1 GENZYME CORPORATION $119.06 10/20/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095337
Principal investigator 1 Genentech, Inc. $2,644.00 10/15/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629989
Principal investigator 1 GENZYME CORPORATION $15,133.56 10/14/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095324
Principal investigator 1 TG Therapeutics, Inc. $23.31 10/07/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199987
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,002.32 10/01/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307595
Principal investigator 1 TG Therapeutics, Inc. $32,799.75 09/30/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199945
Principal investigator 1 GENZYME CORPORATION $16,154.35 09/29/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095319
Principal investigator 1 Genentech, Inc. $121.00 09/25/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629983
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117992
Principal investigator 1 TG Therapeutics, Inc. $24.70 09/23/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199955
Principal investigator 1 TG Therapeutics, Inc. $23.31 09/23/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199957
Principal investigator 1 Genentech, Inc. $2,028.00 09/03/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629977
Principal investigator 1 TG Therapeutics, Inc. $24.70 09/02/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199953
Principal investigator 1 TG Therapeutics, Inc. $5,951.70 08/31/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199943
Principal investigator 1 TG Therapeutics, Inc. $23.31 08/29/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199951
Principal investigator 1 TG Therapeutics, Inc. $5,604.06 08/21/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199971
Principal investigator 1 GENZYME CORPORATION $5,822.35 08/18/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095311
Principal investigator 1 TG Therapeutics, Inc. $24.70 08/18/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199949
Principal investigator 1 Genentech, Inc. $6,215.00 08/15/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629944
Principal investigator 1 GENZYME CORPORATION $12,290.90 08/11/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095305
Principal investigator 1 EMD Serono, Inc. $1,729.00 08/04/2025 Non-covered Recipient Entity
North Central Neurology
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118447
Principal investigator 1 GENZYME CORPORATION $125.00 08/04/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095281
Principal investigator 1 GENZYME CORPORATION $10,587.91 08/04/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095287
Principal investigator 1 TG Therapeutics, Inc. $3,192.75 07/31/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199941
Principal investigator 1 GENZYME CORPORATION $5,540.00 07/28/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095293
Principal investigator 1 GENZYME CORPORATION $125.00 07/28/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095299
Principal investigator 1 TG Therapeutics, Inc. $157.72 07/22/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199947
Principal investigator 1 Genentech, Inc. $2,028.00 07/21/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629968
Principal investigator 1 Genentech, Inc. $2,500.00 07/21/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629973
Principal investigator 1 GENZYME CORPORATION $2,500.00 07/14/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095253
Principal investigator 1 GENZYME CORPORATION $79.06 07/14/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095259
Principal investigator 1 GENZYME CORPORATION $28,096.47 07/02/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095265
Principal investigator 1 GENZYME CORPORATION $1,000.00 07/02/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226095276
Principal investigator 1 Genentech, Inc. $34.34 07/02/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629913
Principal investigator 1 GENZYME CORPORATION $1,500.00 06/23/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095271
Principal investigator 1 Genentech, Inc. $32.98 06/23/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629917
Principal investigator 1 TG Therapeutics, Inc. $400.00 06/17/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199899
Principal investigator 1 TG Therapeutics, Inc. $450.00 06/05/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199895
Principal investigator 1 TG Therapeutics, Inc. $178.77 06/05/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199897
Principal investigator 1 Genentech, Inc. $8,954.00 06/03/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629908
Principal investigator 1 TG Therapeutics, Inc. $3,420.00 06/01/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199893
Principal investigator 1 TG Therapeutics, Inc. $1,700.00 05/28/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199891
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117997
Principal investigator 1 GENZYME CORPORATION $31,931.35 05/19/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095249
Principal investigator 1 TG Therapeutics, Inc. $150.00 05/14/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199889
Principal investigator 1 Genentech, Inc. $22,254.00 05/13/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629937
Principal investigator 1 Genentech, Inc. $2,301.00 05/13/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629964
Principal investigator 1 TG Therapeutics, Inc. $150.00 05/13/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199887
Principal investigator 1 TG Therapeutics, Inc. $2,475.00 05/12/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199885
Principal investigator 1 Celgene Corporation $10,714.35 05/07/2025 Non-covered Recipient Entity
North Central Neurology Associates, PC
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222304719
Principal investigator 1 Genentech, Inc. $2,301.00 04/28/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629957
Principal investigator 1 TG Therapeutics, Inc. $75.00 04/23/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199883
Principal investigator 1 GENZYME CORPORATION $125.00 04/21/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095237
Principal investigator 1 GENZYME CORPORATION $125.00 04/21/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095243
Principal investigator 1 TG Therapeutics, Inc. $107.72 04/17/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199881
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 04/17/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199937
Principal investigator 1 Genentech, Inc. $20.00 04/15/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629940
Principal investigator 1 GENZYME CORPORATION $9,312.10 04/14/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095230
Principal investigator 1 GENZYME CORPORATION $858.40 04/07/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226095187
Principal investigator 1 GENZYME CORPORATION $125.00 04/02/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095212
Principal investigator 1 GENZYME CORPORATION $17,831.35 04/02/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095219
Principal investigator 1 Genentech, Inc. $2,028.00 04/01/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629961
Principal investigator 1 Novartis Pharmaceuticals Corporation $88,033.32 03/31/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190303503
Principal investigator 1 TG Therapeutics, Inc. $1,075.00 03/31/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200019
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117988
Principal investigator 1 GENZYME CORPORATION $35,201.70 03/17/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095176
Principal investigator 1 GENZYME CORPORATION $2,210.00 03/17/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226095193
Principal investigator 1 GENZYME CORPORATION $40.00 03/10/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095199
Principal investigator 1 TG Therapeutics, Inc. $800.00 03/03/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199879
Principal investigator 1 TG Therapeutics, Inc. $2,530.00 02/28/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200017
Principal investigator 1 TG Therapeutics, Inc. $150.00 02/25/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199877
Principal investigator 1 Genentech, Inc. $35,626.00 02/20/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629932
Principal investigator 1 Genentech, Inc. $2,500.00 02/19/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629924
Principal investigator 1 EMD Serono, Inc. $7,766.00 02/13/2025 Non-covered Recipient Entity
North Central Neurology
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118445
Principal investigator 1 EMD Serono, Inc. $441.00 02/13/2025 Non-covered Recipient Entity
North Central Neurology
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118449
Principal investigator 1 GENZYME CORPORATION $40.00 02/10/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095206
Principal investigator 1 Genentech, Inc. $63.65 02/05/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629921
Principal investigator 1 TG Therapeutics, Inc. $5,065.00 01/31/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200015
Principal investigator 1 TG Therapeutics, Inc. $107.72 01/30/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199875
Principal investigator 1 TG Therapeutics, Inc. $200.00 01/29/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199873
Principal investigator 1 Genentech, Inc. $43.76 01/28/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211629929
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,869.80 01/28/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190303501
Principal investigator 1 GENZYME CORPORATION $2,825.00 01/27/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095168
Principal investigator 1 GENZYME CORPORATION $5,822.35 01/27/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095181
Principal investigator 1 Genentech, Inc. $2,028.00 01/17/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211629953
Principal investigator 1 TG Therapeutics, Inc. $98.60 01/17/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199869
Principal investigator 1 TG Therapeutics, Inc. $101.82 01/17/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199871
Principal investigator 1 GENZYME CORPORATION $15,376.35 01/06/2025 Non-covered Recipient Entity
0000203566 North Central Neurology Assocs Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226095224
Principal investigator 1 TG Therapeutics, Inc. $115.00 01/06/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199867
Principal investigator 1 Novartis Pharmaceuticals Corporation $72.00 01/01/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES, PC
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190303499
Principal investigator 1 Novartis Pharmaceuticals Corporation $144,937.03 01/01/2025 Non-covered Recipient Entity
NORTH CENTRAL NEUROLOGY ASSOCIATES PC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307597